Author

Kim Isaacs 1

1 UNC School of Medicine,Chapel Hill,United States

EFFICACY OF VEDOLIZUMAB WITH AND WITHOUT CONTINUED IMMUNOSUPPRESSANT USE IN GEMINI 1 AND GEMINI 2

Brian G. Feagan, Corey A Siegel, Gil Y. Melmed, Kim Isaacs, Karen Lasch, Maria Rosario, Alexandra Green, Brihad Abhyankar

ETROLIZUMAB VERSUS PLACEBO IN TUMOR NECROSIS FACTOR ANTAGONIST NAIVE PATIENTS WITH ULCERATIVE COLITIS: RESULTS FROM THE RANDOMIZED PHASE 3 LAUREL TRIAL

Severine Vermeire, Peter L Lakatos, Timothy Ritter, Stephen B Hanauer, Brian Bressler, Reena Khanna, Kim Isaacs, Saumin Shah, Alysha Khavarian Kadva, Helen Tyrrell, Young Oh, Swati Tole, Akiko Chai, Jennifer Pulley, Wenhui Zhang, Brian G. Feagan

EVALUATION OF SYMPTOM IMPROVEMENT DURING INDUCTION IN PATIENTS WITH CROHN'S DISEASE TREATED WITH MIRIKIZUMAB

William Sandborn, Bruce E. Sands, Pieter Hindryckx, Monika Fischer, Kim Isaacs, April Naegeli, Debra Miller, Elisa Gomez Valderas, Noah Agada, Paul Pollack, Geert R. D'Haens

Item 1 - 3 / 3
1